Vyvo Achieves FDA Approval for Wearable Devices, Merging Blockchain Technology with Healthcare Innovation by Chainwire

SINGAPORE, SINGAPORE, May 14, 2024, Chainwire

Vyvo Smart Chain, a HealthFi ecosystem that rewards health tracking through data monetization, today announced that Vyvo has received clearance from the US Food and Drug Administration (FDA) for LifeWatch, the innovative The company's wearable device for health and wellness tracking. This achievement marks a major breakthrough in the convergence of blockchain technology and health monitoring.

Vyvo's LifeWatch is pioneering a new era in health and wellness. LifeWatch promotes a user-centric health monitoring model and leverages decentralized physical infrastructure network (DePIN) technology to enable users to monetize their health data. This ensures privacy, anonymity, and full ownership and control over personal health data, allowing users to securely manage and monetize their information.

Fabio Galdi, co-founder and CEO of Vyvo, said: “This approval marks a significant step forward in the integration of blockchain technology into health and wellness. “We are committed to innovation and user empowerment, and this FDA clearance positions us to continue to challenge current regulations and lead a transformation in health solutions.”

Vyvo not only provides users with advanced wellness monitoring tools, but also fosters a secure and transparent ecosystem for health data, powered by blockchain technology. By continually pushing the boundaries of digital health management, Vyvo opens new avenues for people to take charge of their well-being.

Vyvo wearables are available at helohealth.com. To learn more about VSC and how to earn rewards through health tracking, users can visit vyvo.com.

About Vyvo Smart Chain

Vyvo Smart Chain is a HealthFi ecosystem that rewards health tracking by monetizing data on IoT devices. Vyvo makes it easy for people to understand and track their body statistics, ensure the privacy of health data, and get rewarded for doing so while contributing to new drug research, developing treatments, and preventing the spread of disease.

Contactmike evans[email protected]

This article was originally published on Chainwire.